肝动脉化疗栓塞联合三维适行放疗治疗原发性肝癌临床疗效观察

目的 评价肝动脉化疗栓塞（TACE）联合三维适行放疗（3DCRT）治疗不能手术的原发性肝癌临床疗效.方法 64例不能手术的原发性肝癌患者分成两组,治疗组（n=34）先行TACE术2～3次,休息2～4周后行3DCRT治疗;对照组（n=30）单纯TACE治疗2～3次.结果 近期疗效瘤体缩小率（CR＋PR）治疗组为73.5%,对照组为36.6%,两组比较差异有统计学意义（P＜0.01）;血清AFP下降治疗组为100%,对照组为92.9%,两组差异无统计学意义（P＞0.05）.远期疗效：1、2、3年生存率治疗组为76.5%、58.8%和41.2%;对照组为56.7%、26.7%和13.3%,两组比较差异有统计学意义（P＜0.05）.结论 TACE联合3DCRT治疗原发性肝癌是一种安全有效的治疗模式,值得临床推广.

Transcatheter arterial chemoembolization therapy combined three-dimensional conformal radiotherapy Clinical observation of primary liver cancer

Objective To evaluate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with three-dimension conformal radiotherapy (3DCRT) in treating unresectable primary Hepatic carcinoma(PHCC).Methods 64 cases of PHCC were randomly divided into 2 groups,TACE combined with 3DCRT group (Treatment group) and TACE alone group (control group).34 cases in treatment group were treated with TACE 2 ～3 times at first,after resting for 2-4 weeks,3DCRT treatment was used.30 cases in control group were treated with TACE 2 ～ 3 times only.Results The percentage of tumor regression rate (CR + PR) was 73.5% in treatment group and 36.6% in control group.The difference was significant (P ＜0.01).The percentage of AFP declined was 100% in treatment group and 92.9% in control group,which difference was not significant (P ＞0.05).The cumulative survival rate of 1-,2-and 3-years were 76.5%,58.8% and 41.2% in treatment group,and 56.7%,26.7%,13.3% in control group respectively.There was significant difference between the two groups (P ＜ 0.05).Conclusion The treatment of TACE combined with 3DCRT is an effective and security treatment method for primary Hepatic carcinoma.